SFA THERAPEUTICS
SFA Therapeutics is a development-stage bio-pharmaceutical startup company focused on a new advancement in the treatment of chronic inflammatory disease - the use of microbiome-derived metabolites as drugs.
SFA THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
Jenkintown, Pennsylvania, United States
Country:
United States
Website Url:
http://www.sfatherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
1-267-584-1080
Email Addresses:
[email protected]
Total Funding:
4.1 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Wordpress Plugins Mobile Non Scaleable Content
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Artielle ImmunoTherapeutics
Artielle ImmunoTherapeutics develops recombinant T-cell receptor ligands to treat T-cell-mediated inflammatory diseases.
Atomo Coffee
Atomo Coffee is a developer of molecular coffee.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Beta Therapeutics
Beta Therapeutics provides service for medical research.
Carmot Therapeutics
Carmot Therapeutics provides drugs to treat inflammatory, metabolic, and neurological diseases.
Elgia Therapeutics
Elgia Therapeutics is a biopharmaceutical company.
Enterprise Therapeutics
A UK-based developer of drugs to treat respiratory diseases
EOS Remediation
EOS Remediation is a developer of products that treat contaminated soil and groundwater.
ERAD Therapeutics
ERAD Therapeutics is a developer of a drug platform designed to create novel biological agents to treat orphan diseases
GT Apeiron Therapeutics
GT Apeiron Therapeutics is a developer of innovative drugs utilizing artificial intelligence technology.
Nitrase Therapeutics
Nitrase Therapeutics is developing drugs against newly discovered nitration enzyme(s).
Odyssey Therapeutics
Odyssey Therapeutics provides medicines to patients with inflammatory diseases and cancer.
Orbus Therapeutics
Orbus Therapeutics is dedicated to developing products that treat rare diseases.
Recludix Pharma
Recludix pharma is a developing platform to treat cancer patients.
scibac
SciBac is a developer of biotherapeutics intended to treat antibiotic diseases.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
SynAct Pharma
SynAct Pharma develops drugs for acute deterioration in inflammatory diseases.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Employees Featured
Founder
Investors List
Boost VC
Boost VC investment in Seed Round - SFA Therapeutics
Acequia Capital (AceCap)
Acequia Capital (AceCap) investment in Seed Round - SFA Therapeutics
INP Capital
INP Capital investment in Seed Round - SFA Therapeutics
North South Ventures
North South Ventures investment in Seed Round - SFA Therapeutics
Savantus Ventures
Savantus Ventures investment in Seed Round - SFA Therapeutics
Asymmetry Ventures
Asymmetry Ventures investment in Seed Round - SFA Therapeutics
Reinforced Ventures
Reinforced Ventures investment in Seed Round - SFA Therapeutics
Ben Franklin Technology Partners of Southeastern Pennsylvania
Ben Franklin Technology Partners of Southeastern Pennsylvania investment in Grant - SFA Therapeutics
Official Site Inspections
http://www.sfatherapeutics.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "SFA Therapeutics"
SFA Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 1-267-584-1080 SFA Therapeutics is a development-stage bio-pharmaceutical startup company focused on a new …See details»
Home_Main – SFAtx - sfatherapeutics.com
Our pipeline includes treatments for Psoriasis, Liver Cancer (Hepatitis B, NASH and HCC), Ophthalmic Diseases, Cytokine Release Syndrome- a side effect in CAR-T, Prevention of …See details»
TEAM | Sfa Therapeutics 1
610 Old York Rd, Suite 400, Jenkintown, Pennsylvania 19046, United StatesSee details»
SFA Therapeutics - LinkedIn
SFA Therapeutics | 478 followers on LinkedIn. A New Paradigm in Drug Development | SFA Therapeutics is a clinical stage start-up biotech company developing compounds discovered in …See details»
SFA Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials
Www.sfatherapeutics.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding(NIH) Investment. Financing. Overview. Tags. ... The …See details»
SFA Therapeutics - VentureRadar
Similar Companies: Solarea Bio, Inc. USA Privately Held The Solarea breakthrough came from the combined efforts of the company’s co-founders who established a link between the …See details»
SFA Therapeutics - Overview, News & Similar companies - ZoomInfo
Jan 3, 2023 SFA Therapeutics Announces FDA Clearance for Amendment to Extend Phase 1b Trial of SFA-002 for Psoriasis JENKINTOWN, Pa., Jan. 11, 2023 /PRNewswire/ -- SFA …See details»
SFA Therapeutics - Ben Franklin Technology Partners
[email protected]. Dr. Ira C. Spector CEO. Dr. Mark Feitelson CSO. Dr. Alla Arzumanyan CDO. Mr. James Kirwin COO. Dr. King Lee VP Regulatory Affairs. Ben Franklin …See details»
News Archive – SFAtx - sfatherapeutics.com
Dec 22, 2017 Houston organization names 10 most promising life sciences startups Read More. November 16, 2020 READ MORE . Announcing BioNJ’s BioPartnering Company & Pitch …See details»
SFA Therapeutics, Inc. - BIO CEO & Investor Conference | BIO
SFA Therapeutics is a clinical-stage oral small molecule, novel immunomodulatory focused company pursuing chronic inflammatory and autoimmune diseases with significant unmet …See details»
SFA Therapeutics Strengthens Management Team with …
JENKINTOWN, Pa., July 16, 2024 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the …See details»
SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation …
PHILADELPHIA, Oct. 28, 2019 /PRNewswire/ -- SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) ...See details»
Shawn O'Brien | Sfa Therapeutics 1
Shawn O'Brien is a seasoned pharmaceutical executive currently serving as a Chairman of the Board at SFA Therapeutics, Inc. H e also serves as a Chief Executive Officer & Managing …See details»
SFA Therapeutics Wins U.S. Patent for Use of Short ... - Business Wire
Dec 5, 2018 According to the World Health Organization, "an estimated 257 million people are living with hepatitis B, which resulted in over 887,000 deaths in 2015. ... Dr. Ira C. Spector …See details»
SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation …
Oct 28, 2019 While hepatocellular carcinoma afflicts 54,000 patients a year in the US (Cancer.net), the World Health Organization estimates the disease causes as many as …See details»
News – SFAtx - sfatherapeutics.com
SFA-002 Updated Extension Data Showing 92% PASI 50 and 72% PASI 75 $4.5 Million Bridge Financing led by North South Ventures Composition of Matter patent which covers over 40 …See details»
SFA Therapeutics Selected as 2021 Company and Pitch …
"On Behalf of the Millions of Patients Who Suffer from Autoimmune Diseases, we are Delighted that Our Work is Beginning to Gain Recognition”See details»
SFA Therapeutics Announces FDA Approval To Begin IND Trial
PHILADELPHIA, June 29, 2020 /PRNewswire/ -- SFA Therapeutics, Inc. is pleased to announce that the US FDA has provided approval to conduct a clinical trial (officially referred to as an …See details»
SFA Therapeutics Announces FDA Clearance for Amendment to …
JENKINTOWN, Pa., Jan. 11, 2023 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing new, microbiome-based therapeutics for the treatment …See details»